Innovating Sustainably

At BeiGene, we recognize that human health and the health of the planet are intrinsically linked. Scientific studies show that higher levels of pollution correlate with higher incidences of disease, including some forms of cancer. Moreover, climate change impacts continue to grow in scale and intensity, increasing the risk of disruptions to our business and our ability to provide care to our patients. As a company focused on improving health and health equity, we believe it is imperative to operate our business in a way that mitigates our environmental impacts beginning with climate change.


New Climate Strategy

BeiGene will set a quantitative Scope 1 and 2 emissions goal by 2024 and plans to set a quantitative Scope 3 emissions goal by 2025. In 2022, we are building a strategic roadmap that includes energy efficiency projects and renewable energy purchases.  We will begin conducting energy audits in our R&D and manufacturing facilities, which account for the majority of our Scope 1 and 2 emissions. We are also assessing how to best reduce GHG emissions across our value chain.

Environmental Performance

Our ability to rapidly develop and commercialize new medicines is helping us bring innovative, life-saving medicines to millions more patients globally. To meet the growing demand for our medicines, we are investing in additional laboratory space and manufacturing capacity, resulting in increased GHG emissions, water use, and waste creation. While our overall resource use is projected to increase, we are working to improve our efficiency, producing more product with fewer inputs per batch.

Sustainability Goals

  • Set a quantitative Scopes 1 and 2 emissions goal by 2024
  • Set a quantitative Scope 3 target by 2025. To advance this goal, we will engage with two-thirds of our raw material supplier base (using 2021 spend information)